We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

BIO-RAD LABORATORIES

Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Multiplex Assay Identifies Diarrheagenic Escherichia coli

By LabMedica International staff writers
Posted on 14 Aug 2014
A rapid, reliable and repeatable method is urgently needed for identifying diarrheagenic Escherichia coli (DEC) so as to provide the reference for responding to diarrheal disease outbreaks and the treatment of the diarrheal patients associated with DEC.

A multiplex real-time polymerase chain reaction (PCR) assay based multicolor-combinational probe coding (MCPC) for the identification of eight foodborne pathogens has been developed and applied to the rapid diagnosis of a foodborne disease outbreak successfully.

Molecular biologists at the Xiamen University (China) designed specific primers and modified molecular beacon probes of nine specific virulence genes, whose 5′ end were added with homo tail sequence. More...
They developed and optimized a two-tube modified molecular beacon based multiplex real-time PCR (rtPCR) assay for the identification of five Escherichia coli pathotypes.

A total of 102 bacterial strains, including 52 reference bacterial strains and 50 clinical strains, were isolated to confirm whether the target genes selected were specific. The detection limits of the assay were then tested. Lastly, the assay was applied to the detection of 11,860 clinical samples to evaluate the specificity and sensitivity of the developed assay compared with the conventional PCR. Multiplex rtPCR reactions were performed on the Bio-Rad CFX 96 Real-Time PCR System (Bio-Rad; Hercules, CA, USA).

The target genes were 100% specific as assessed on 102 bacterial strains since no cross-reactions were observed. The detection limits ranged from 88 colony forming units (CFU)/mL for Enterohemolysin E. coli (EHEC) to 880 CFU/mL Enteropathogenic E. coli (EPEC). Compared with the conventional PCR, the specificity and sensitivity of the multiplex rtPCR was 100% and over 99%, respectively. The coefficient of variation (CV) for each target gene ranged from 0.45% to 1.53%. Of the 171 positive clinical samples, 111 (64.9%) were identified as Enterotoxigenic E. coli (ETEC) and 38 (22.2%) as Enteropathogenic E. coli which were the dominating pathotypes of DEC strains.

The authors concluded that they had developed a rapid and effective two-tube multiplex rtPCR for the identification of all DEC pathotypes. This method took only 90 minutes and saved resources including biochemical reagents, disposable medical supplies and could be used in clinical and public health laboratories. The study was published on July 15, 2014, in the journal Annals of Clinical Microbiology and Antimicrobials.

Related Links:

Xiamen University
Bio-Rad



New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.